Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACTIQ® Clear all
Completed Phase 2 Interventional

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

NCT00236041
View directory record Official record
Conditions
Cancer, Breakthrough Pain
Interventions
ACTIQ®
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Not applicable Interventional Results available

Anesthesia in Patients With Mitochondrial Disease

NCT02053766
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Sevoflurane, Dexmedetomidine, Propofol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery

NCT00804609
View directory record Official record
Conditions
Epidural Analgesia, Obstetric
Interventions
DepoDur following epidural lidocaine, DepoDur following spinal anesthetic
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

NCT02138396
View directory record Official record
Conditions
Bioavailability
Interventions
Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

NCT01761565
View directory record Official record
Conditions
Plasma Concentrations
Interventions
Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated No phase listed Observational

An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.

NCT01901718
View directory record Official record
Conditions
Breakthrough Pain
Interventions
Not listed
Lead sponsor
International Clinical Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Fentanyl Single and Multidose PK

NCT00402350
View directory record Official record
Conditions
Breakthrough Pain
Interventions
Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

NCT01173627
View directory record Official record
Conditions
Pain
Interventions
Test fentanyl citrate 400 mcg troche, Actiq 400 mcg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971
View directory record Official record
Conditions
Peer Review, Research
Interventions
Intravenous fentanyl citrate, Duragesic®, Mylan generic fentanyl
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

NCT01780233
View directory record Official record
Conditions
Pain
Interventions
Fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, Fentanyl citrate injection 100 µg intravenously, Naltrexone 50 mg
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fentanyl Sublingual Spray in Opioid Naive Participants

NCT02641340
View directory record Official record
Conditions
Pharmacology
Interventions
Fentanyl Sublingual Spray, Fentanyl Citrate IV
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

NCT01660763
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Damascus, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Phoenix, Arizona • Loma Linda, California • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 2, 2026, 6:33 AM EDT
Withdrawn Phase 2 Interventional

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

NCT02137525
View directory record Official record
Conditions
Acute Pain
Interventions
Morphine 6 mg, Fentanyl 100 µg, Fentanyl 200 µg, Fentanyl 400 µg, Placebo Sublingual Spray, Intravenous Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Phoenix, Arizona • Sylmar, California • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates

NCT00286143
View directory record Official record
Conditions
Congenital Cystic Adenomatoid Malformation
Interventions
Fentanyl
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 6 Months
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 2, 2026, 6:33 AM EDT
Completed No phase listed Observational

Observational Registry Study of Quality of Life When Treating BTcP With Abstral

NCT01936636
View directory record Official record
Conditions
Quality of Life, Breakthrough Cancer Pain
Interventions
Fentanyl
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Mobile, Alabama • Peoria, Arizona • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

NCT00648414
View directory record Official record
Conditions
Healthy
Interventions
Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

NCT01549002
View directory record Official record
Conditions
Abscess, Pain
Interventions
Intranasal Fentanyl, Intravenous Morphine
Drug
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

NCT06719986
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene HCl injection, Naloxone HCl intranasal
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 2, 2026, 6:33 AM EDT